Sharon Avkin-Nachum

This inventor holds 21 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Oligonucleotide Therapeutics. Top assignees: Quark Pharmaceuticals, Inc., Nitto-Denko Corporation, Bio-Lab, Inc.. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sharon Avkin-Nachum. Retrieved from https://idiyas.com/inventor/sharon-avkin-nachum

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 5)

% Patents Active = 28.6

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 85(Granted Patents)

Location History:

Nes Ziona, IL (2014 - 2018)
Nes Zionna, IL (2014 - 2020)

Company Filing History:

16 out of 67

Quark Pharmaceuticals, Inc.

patents

3 out of 3,949

Nitto-Denko Corporation

Washington University

patents

where one patent can have more than one assignee

Years Active: 2014-2020

Loading Chart...

Areas of Expertise:

Double-Stranded Oligonucleotides

siRNA Compounds

Therapeutic Oligonucleotides

HSP47 Modulation

Toll-Like Receptor Pathway

Nucleotide Analogues

Lung Disease Treatment

Sphingolipid Compounds

Positional Modifications

Non-Nucleotide Overhangs

DDIT4 Targeting

RhoA Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10781449 - Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof (2020-09-22),

2. 10494631 - siRNA compounds comprising terminal substitutions (2019-12-03),

3. 10421962 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2019-09-24),

4. 10144928 - Double stranded oligonucleotide compounds comprising positional modifications (2018-12-04),

5. 10093923 - Modulation of HSP47 expression (2018-10-09),

6. 10059942 - Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues (2018-08-28),

7. 9932578 - Double-stranded oligonucleotide molecules to P53 and methods of use thereof (2018-04-03),

8. 9889200 - Sphingolipid-polyalkylamine-oligonucleotide compounds (2018-02-13),

9. 9822362 - Compositions and methods for treating lung disease and injury (2017-11-21),

10. 9796979 - Oligonucleotide modulators of the toll-like receptor pathway (2017-10-24),

11. 9701960 - siRNA compounds comprising terminal substitutions (2017-07-11),

12. 9611474 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2017-04-04),

13. 9611473 - Double-stranded nucleic acid compounds (2017-04-04),

14. 9487778 - Oligonucleotide modulators of the toll-like receptor pathway (2016-11-08),

15. 9249414 - Oligonucleotide compounds comprising non-nucleotide overhangs (2016-02-02),

Title: The Innovative Work of Sharon Avkin-Nachum in Gene Therapy

Introduction: Sharon Avkin-Nachum, based in Nes Zionna, IL, is a distinguished inventor recognized for his contributions to the field of nucleic acids and gene therapy. With an impressive portfolio of 21 patents, Avkin-Nachum has pioneered advances that hold promise for treating various diseases and disorders through innovative technology.

Latest Patents: Among his most recent patent filings are "Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof," which involves chemically synthesized nucleic acid compounds designed to down-regulate the expression of the p53 gene. This invention expands the possibilities for treating a range of conditions linked to gene expression. Another notable patent is focused on "siRNA compounds comprising terminal substitutions," which relates to modified small interfering RNA (siRNA) compounds that also aim to down-regulate target gene expression. This innovative approach contributes to pharmaceutical compositions that are geared toward treating and preventing severities of diseases related to specific genes.

Career Highlights: Throughout his career, Sharon Avkin-Nachum has worked with prominent companies such as Quark Pharmaceuticals, Inc. and Nitto Denko Corporation. His efforts within these organizations have been vital for advancing therapeutic applications in genetic research. His extensive experience in biotechnology has cultivated a robust understanding of creating valuable solutions drawn from cutting-edge research.

Collaborations: Avkin-Nachum has collaborated with notable colleagues including Elena Feinstein and Hagar Kalinski. These partnerships have fostered an environment of innovation, facilitating the exchange of ideas and enabling the development of groundbreaking technologies in the realm of molecular biology and gene therapy.

Conclusion: Sharon Avkin-Nachum's innovative spirit and dedication to advancing the field of gene therapy are evident in his numerous patents and collaborative efforts. His work showcases the critical role of creativity and scientific inquiry in addressing complex health challenges. As the field of biotechnology continues to evolve, the contributions of inventors like Avkin-Nachum will undoubtedly pave the way for new discoveries and treatments.

Profile summary based on public USPTO records.